Cat. No. 4481
Chemical Name: N-[4-[(6,7-Dimethoxy-4-quinolinyl)o
Biological ActivityInhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC50 values are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFRβ and c-Kit respectively). Does not inhibit Flt3, EGFR or c-Src. Suppresses osteoclast differentiation and osteolysis in a rat bone metastasis model.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Ohno et al (2006) A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol.Cancer Ther. 5 2634. PMID: 17121910.
Ohno et al (2007) The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur.J.Immunol. 38 283. PMID: 18085662.
Kubota et al (2009) M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J.Exp.Med. 206 1089. PMID: 19398755.
If you know of a relevant citation for this product please let us know.
Keywords: Ki 20227, supplier, Ki20227, c-Fms, macrophage, colony-stimulating, factor, receptors, M-CSFR, CSF1R, inhibitors, inhibits, osteolysis, osteoclast
Find multiple products by catalog number
New Products in this Area
Potent PDGFR and VEGFR inhibitorNVP ADW 742
ATP-competitive inhibitor of IGF1RKRCA 0008
Potent Ack1 and ALK dual inhibitor; orally bioavailableDDR1-IN-1 dihydrochloride
Selective DDR1 inhibitorHNGF6A
Humanin analog; increases insulin sensitivityHNGF6A
Humanin analog; increases insulin sensitivityGSK 1838705
Potent and selective IR and IGF1R inhibitor; antitumorGSK 1838705
Potent and selective IR and IGF1R inhibitor; antitumorSUN 11602
Basic fibroblast growth factor (bFGF) mimetic; neuroprotectiveSUN 11602
Basic fibroblast growth factor (bFGF) mimetic; neuroprotective
October 5 - 8, 2014